经营活动现金流为负

港股IPO招股书披露先例 · 164 家公司,164 项

经营活动现金流为负,指公司在往绩期间经营活动所用现金净额为负数。招股书一般在概要、风险因素、业务及财务资料章节披露各期净流出金额及成因,如收入增长带动营运资金增加、研发投入或回款滞后,并说明股东出资、股权或债务融资等来源,提出预期转正及加强应收款项管理、成本控制等改善措施,部分亦声明营运资金足以应付未来十二个月需求。

2026-06-23Prospectus
安克创新科技股份有限公司Anker Innovations Technology Co., Ltd.00668.HK

2026年第一季度经营活动现金净流出

For the three months ended March 31, 2026, our net cash used in operating activities was RMB450.6 million, which was primarily attributable to profit before taxation of RMB558.7 million, partially offset by tax paid of RMB141.2 million, adjusted for certain non-cash and non-operating items, including (i) increase in inventories from RMB4,997.1 million as of December 31, 2025 to RMB5,568.9 million as of March 31, 2026 and (ii) a decrease in contract liabilities from RMB552.5 million as of December 31, 2025 to RMB335.4 million as of March 31, 2026.

Financial Information · 第 239 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-06-22Prospectus
浙江来福谐波传动股份有限公司Zhejiang Laifual Drive Co., Ltd.03952.HK

往绩记录期间经营现金流持续净流出

We recorded net cash used in operating activities of RMB35.2 million, RMB33.7 million and RMB63.4 million in 2023, 2024 and 2025, respectively.

Business · 第 166 页

Against the background of long cash conversion cycle and the mismatch of the cash receipts from trade receivables and payments for trade payables during the Track Record Period, we recorded net operating cash outflows throughout the Track Record Period.

Financial Information · 第 236 页

Going forward, we will continue to implement inventory management measures to enhance inventory turnover and working capital status.

Financial Information · 第 236 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-06-18Application Proof
广州知易生物科技股份有限公司Guangzhou Zhiyi Biotechnology Co., Ltd.

经营活动现金净流出4,500万及2,270万元

During the Track Record Period, we recorded net cash used in operating activities of RMB45.0 million in 2024 and RMB22.7 million in 2025.

Financial Information · 第 237 页

To fund our operations, we have relied primarily on equity financing from investors.

Financial Information · 第 237 页

In 2024, we completed Series C financing rounds, receiving RMB77.0 million in capital contributions by investors, which significantly strengthened our cash position.

Financial Information · 第 237 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-06-18Application Proof
石药创新制药股份有限公司CSPC Innovation Pharmaceutical Co., Ltd.

2024及2025年经营活动现金净流出

Net cash generated from/(used in) operating activities | 660,956 | (1,140,405) | (296,013)

Business · 第 183 页

Looking ahead, we expect our operating cashflow to stabilize in subsequent periods, as our revenue is anticipated to grow and we continue to improve our operational efficiency.

Business · 第 186 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-06-17Prospectus

经营活动现金流量为负

As the MGR Group is currently in its development phase, it has negative operating and investing cash flows, while financing cash flows are positive.

Financial Information · 第 257 页

This is due to the limited revenue generated by the MGR Group from mining equipment rentals and the high capital expenditure required to complete the construction of mining infrastructure and processing facilities.

Financial Information · 第 257 页

Net cash flows used in operating activities | (16,489) | (6,281) | (21,714)

Financial Information · 第 258 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-06-15Application Proof

经营活动现金流出连续三年为负

Our net cash used in operating activities in the years ended December 31, 2023, 2024 and 2025 was primarily attributable to our continued investment in building up our NHPs for breeding and the impact of market conditions on our nonclinical study service business.

Summary · 第 10 页

Excluding cash payments for NHPs for breeding, we recorded net cash generated from operating activities in each period.

Summary · 第 10 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-06-15Prospectus
陕西麦科奥特医药科技股份有限公司Shaanxi Micot Pharmaceutical Technology Co., Ltd.02335.HK

往绩记录期间经营活动现金净流出

We recorded net cash used in operating activities of RMB107.7 million and RMB137.1 million for 2024 and 2025, respectively.

Financial Information · 第 262 页

During the Track Record Period and up to the Latest Practicable Date, we had financed our operations primarily through equity and debt financing and we had not experienced any difficulty in obtaining such financing.

Financial Information · 第 262 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-06-15Application Proof
凌科药业(浙江)股份有限公司Lynk Pharmaceuticals Co., Ltd.

往绩记录期间经营活动现金净流出

During the Track Record Period, we funded our working capital requirements through equity financing.

Financial Information · 第 230 页

While we had net operating cash outflows during the Track Record Period, we believe our liquidity requirements will be satisfied by using funds from a combination of our cash and cash equivalents, net [REDACTED] from the [REDACTED] and other funds raised from the capital markets from time to time.

Financial Information · 第 230 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-06-15Prospectus
上海仙工智能科技股份有限公司Shanghai Seer Intelligent Technology Co., Ltd.06106.HK

往绩记录期间经营活动现金净流出

We recorded a net loss and had net operating cash outflows during the Track Record Period.

Financial Information · 第 240 页

In 2024, we incurred net cash outflows in operating activities primarily due to a rapid growth in our trade receivables as a result of our enlarged business scale.

Financial Information · 第 248 页

We plan to adopt an incentive mechanism that links sales team’s performance-based bonuses directly to their collections of trade receivables.

Financial Information · 第 240 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-06-12Application Proof
烟台蓝纳成生物技术股份有限公司Yantai Lannacheng Biotechnology Co., Ltd.

经营活动现金流出逐年扩大

We recorded net cash flows used in operating activities of RMB132.0 million and RMB143.3 million in 2024 and 2025, respectively.

Financial Information · 第 272 页

During the Track Record Period, we primarily funded our working capital requirements through equity financing.

Financial Information · 第 272 页

Our Directors are of the opinion that, taking into account the financial resources available to us, including cash and cash equivalents of RMB188.5 million as of April 30, 2026 and the estimated [REDACTED] from the [REDACTED], and considering our cash burn rate, we have available sufficient working capital to cover at least 125% of our costs, including research and development costs, administrative expenses, and other operating costs, for at least the next 12 months from the date of this document.

Financial Information · 第 274 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-05-29Application Proof
上海果纳半导体技术股份有限公司Shanghai GoNa Semiconductor Technology Co., Ltd.

2023及2024年经营活动现金净流出

We have historically financed our operations primarily through a consolidation of cash flow generated from our operations, proceeds from Pre-[REDACTED] Investments, and interest-bearing borrowings.

Financial Information · 第 225 页

Net cash flows (used in)/generated from operating activities | (76,329) | (25,340) | 1,024

Financial Information · 第 225 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-05-29Application Proof

往绩记录期间经营活动现金流出持续为负

We experienced negative operating cash flows during the Track Record Period.

Financial Information · 第 221 页

Based on our available cash and cash equivalents, and despite the net operating cash outflows during the Track Record Period, we believe our cash balance is sufficient to meet our operating needs and support our planned expansion.

Financial Information · 第 221 页

Our accumulated deficit as of January 1, 2023, as well as net losses, adjusted net losses (non-IFRS measures), and net operating cash outflows during the Track Record Period primarily reflect these deliberate early-stage commitments.

Summary · 第 11 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-05-29Application Proof
无锡车联天下智能科技股份有限公司Wuxi Autolink Intelligence Tech Co., Ltd.

往绩记录期间经营现金流出持续为负

We had negative operating cash flow of RMB697.0 million, RMB1,011.1 million and RMB872.2 million in 2023, 2024 and 2025, respectively.

Financial Information · 第 259 页

Taking into account the financial resources available to us, including our cash and cash equivalents on hand, unutilized bank facilities, internally generated funds and the estimated [REDACTED] from the [REDACTED], our Directors are of the view that we have sufficient working capital to meet our present needs and for the next 12 months from the date of this document.

Financial Information · 第 259 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-05-29Application Proof
浙江力积存储科技股份有限公司Zhejiang Zentel Memory Technology Co., Ltd.

经营活动现金流连续三年净流出

We recorded net cash outflows from operating activities in 2023, 2024 and 2025, amounting to RMB62.9 million, RMB18.2 million and RMB192.1 million, respectively, mainly due to our loss before tax amounting to RMB245.2 million, RMB109.8 million and RMB11.1 million in the respective years.

Summary · 第 7 页

We plan to improve our net operating cash outflows position by (i) enhancing inventory management, and (ii) optimizing our receivables and payables.

Summary · 第 7 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-05-28Prospectus
天辰生物医药(苏州)股份有限公司LongBio Pharma (Suzhou) Co., Ltd.01779.HK

经营活动现金持续净流出

We recorded net cash flows used in operating activities of RMB104.1 million and RMB121.0 million for the years ended December 31, 2024 and 2025, respectively.

Financial Information · 第 241 页

During the Track Record Period and up to the Latest Practicable Date, we have primarily funded our working capital requirements through equity financing and debt financing.

Financial Information · 第 241 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-05-28Application Proof
麓鹏制药有限公司Lupeng Pharmaceutical Ltd.

经营活动所用现金净额持续为负

During the Track Record Period, we incurred negative cash flows from our operations and substantially all of our operating cash outflows resulted from our R&D and administrative activities.

Financial Information · 第 238 页

We expect to generate more cash flow from our operating activities through the launch and commercialization of our products, enhanced cost containment capacity and operating efficiency, as well as potentially from collaboration and/or licensing arrangements.

Financial Information · 第 238 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-05-28Application Proof
扬州纳力新材料科技股份有限公司Yangzhou Nanopore Innovative Materials Technology Co., Ltd.

连续三年经营活动现金净流出

In 2023, 2024 and 2025, we recorded net cash used in operating activities of RMB164.8 million, RMB338.2 million and RMB297.1 million, respectively.

Business · 第 162 页

Together with our loss-making operations, these factors contributed to our net cash used in operating activities during the Track Record Period.

Business · 第 158 页

Going forward, we plan to strengthen customer credit assessment, payment tracking and collection procedures, improve inventory planning based on production schedules and sales forecasts and manage procurement, prepayments and deposits based on actual production and project needs.

Business · 第 162 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-05-28Application Proof
苏州天瞳威视电子科技股份有限公司Suzhou Calmcar Electronics Technology Co., Limited

往绩期间经营活动现金净流出

(iii) notwithstanding the operating losses and net cash operating outflows during the years ended December 31, 2023, 2024 and 2025, the expected commercialization and revenue growth prospects did not indicate impairment

Financial Information · 第 199 页

However, we expect our net operating cash flow to turn positive in 2026, primarily driven by the collection of a substantial portion of our outstanding trade receivables, resulting in an overall improvement in our cash flow position.

Summary · 第 16 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看

Tell us